{"id":54,"date":"2026-04-08T09:23:23","date_gmt":"2026-04-08T09:23:23","guid":{"rendered":"https:\/\/www.merckconnect.com\/ohtuvayre\/?page_id=54"},"modified":"2026-08-21T20:54:23","modified_gmt":"2026-08-21T20:54:23","slug":"home","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/ohtuvayre\/","title":{"rendered":"Home"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
<\/div>\"\"
Actor Portrayal<\/div><\/div><\/picture>
\"For<\/div>
\"For<\/div>

OHTUVAYRE\u00ae (ensifentrine) is a first-in-class approach to bronchodilation<\/strong> and non-corticosteroid anti-inflammation<\/strong> for COPD maintenance treatment in adults.1,2<\/sup><\/mark><\/h1>

<\/p>

\n\n\n
Explore the data<\/span><\/a><\/div>\n\n\n\n

<\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
<\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n\n

Novel mechanism of action for a broad population1<\/sup><\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

OHTUVAYRE is a selective dual inhibitor of PDE3 and PDE4 and may fit into COPD maintenance treatment conversations, including persistently symptomatic patients and those on dual or triple therapy. <\/p>\n\n\n\n

<\/div>\n\n\n\n

ENHANCE-1 and ENHANCE-2 did not include patients receiving LABA + LAMA or LABA + LAMA + ICS.1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
Explore the MOA<\/span><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Demonstrated efficacy<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

See Efficacy Data in the ENHANCE clinical trials.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
See the study results<\/span><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

The Merck Access Program (MAP) for OHTUVAYRE<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

Verona Pathway Plus is transitioning to The Merck Access Program. Patients and providers may see both names during this time, but your support will remain uninterrupted.<\/p>\n\n\n\n

<\/div>\n\n\n\n

The MAP for OHTUVAYRE may be able to help answer questions and provide information about:<\/p>\n\n\n\n\n

\n